Highlights Cognition Therapeutics, Inc.

Equities

CGTX

US19243B1026

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-13 EDT			5-day change	1st Jan Change
1.95 ^USD	+0.52%		-2.01%	+5.41%

05-07	Cognition Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-29	Cognition Therapeutics, Inc. Completes Enrollment in Phase 2 SHIMmer Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cognition Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Cognition Therapeutics, Inc. Completes Enrollment in Phase 2 SHIMmer Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies	04-29	CI
Cognition Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Cognition Therapeutics, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023	03-11	CI
Cognition Therapeutics, Inc. Presents Analyses at AD/PD 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer?s Disease Studies	03-06	CI
Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-To-Mod Moderate Alzheimer's Disease	11-07	CI
Cognition Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02	CI
Cognition Therapeutics, Inc. and Collaborators At Yale and ACTC Announce Oral Late-Breaking Presentation on the Start Study in Early Alzheimer?s Disease At CTAD	23-10-27	CI
Cognition Therapeutics, Inc. Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease At CTAD	23-10-24	CI
Cognition Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Companies in Alzheimer's race after US nod for Eisai/Biogen drug	23-07-07	RE
Cognition Therapeutics, Inc. and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 Start Study in Early Alzheimer's Disease	23-07-05	CI
Cognition Therapeutics, Inc. Announces Positive Topline Results for CT1812 Phase 2 Sequel Study for Mild-To-Moderate Alzheimerâ€™s Disease	23-06-28	CI
Cognition Therapeutics, Inc. Publishes Clinical Evidence that CT1812 Displaces Aß Oligomers from Binding to Neuronal Synapses in Alzheimer’s Disease	23-05-18	CI
COGNITION THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	23-05-04	AQ
Cognition Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Cognition Therapeutics to Present Analysis Showing Impact of Ct1812 on Pathways Implicated in Dry Age-Related Macular Degeneration At Arvo 2023	23-04-19	CI
Faron Appoints James O'Brien, CPA, MBA as Chief Financial Officer	23-03-30	AQ
Cognition Therapeutics, Inc. Presents Proteomic Biomarker Data Demonstrating Prominent Effects of CT1812 in Altering Underlying Alzheimer's Disease Processes	23-03-28	CI
COGNITION THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-03-23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cognition Therapeutics, Inc.

Equities

CGTX

US19243B1026

Highlights

Filters